Specific biomarkers of response to antiangiogenic therapy

Close metadata

Recommended articles:

Pathogenetic role of multifunctional protein alpha-2-macroglobulin and its activity in tears and serum in age-related macular degeneration and proliferative diabetic retinopathy. Russian Annals of Ophthalmology. 2023;(6):26-32

Prognosis criteria of optical coherence tomography angiography for the long-term efficacy of anti-VEGF therapy of neovascular age-related macular degeneration. Russian Annals of Ophthalmology. 2023;(6):50-58

Salzmann nodular degeneration: pathogenesis, clinical characteristics and treatment. Russian Annals of Ophthalmology. 2023;(6):129-135

Choroidal neovascularization in central serous chorioretinopathy. Russian Annals of Ophthalmology. 2023;(6):152-157

Structural and functional features of the eye in Marfan syndrome. Report 1. Changes in the fibrous tunic of the eye. Russian Annals of Ophthalmology. 2024;(1):5-10

Predicting the effectiveness of organ-preserving treatment of choroidal melanoma using optical coherence tomography data. Russian Annals of Ophthalmology. 2024;(2-2):16-20

Outcomes of bimanual vitreoretinal surgery in the treatment of diabetic retinopathy complications. Russian Annals of Ophthalmology. 2024;(2-2):21-27

Application of optical coherence tomography in the assessment of the posterior lens capsule during anti-angiogenic therapy. Russian Annals of Ophthalmology. 2024;(2-2):28-33

Anatomo-functional state of the central retina in premature infants with intraventricular hemorrhage and retinopathy of prematurity. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(1):66-75

Artificial neural network in intravascular imaging. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(1):77-81

Age-related macular degeneration (AMD) and diabetic macular edema (DME) are the main causes of blindness in the elderly and loss of central vision in patients with diabetic retinopathy, respectively. Anti-VEGF therapy is currently the gold standard for treatment of such patients; it has proved its effectiveness in both randomized clinical trials and clinical practice. However, it should be taken into account that the extent of therapeutic response varies depending on individual characteristics of patients, including the presence of biomarkers that predict the therapeutic response. Numerous studies have discovered a variety of biomarkers for patients with DME and AMD, but their reliability differs and not all of them are eligible for predicting the effectiveness of the treatment. Compared to full clinical examination, biomarkers can offer shorter clinical study duration and lower costs. Most of the specific biomarkers for predicting the response to antiangiogenic therapy are identified using optical coherence tomography. The purpose of this article is to provide contemporary data on the diagnosis and treatment of patients depending on the presence of specific biomarkers.

Keywords:

diabetic macular edema

age-related macular degeneration

optical coherence tomography

anti-VEGF therapy

Authors:

Budzinskaia M.V.

FGBU "Nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ" RAMN, Moskva

SPIN RSCI: 3552-7061
Scopus AuthorID: 6508005851
ResearcherID: C-3026-2014
ORCID: 0000-0002-5507-8775

Fursova A.Zh.

State Novosibirsk Regional Clinical Hospital, 130 Nemirovicha-Danchenko St., Novosibirsk, Russian Federation, 630087

Pedanova E.K.

S. Fyodorov Eye Microsurgery Federal State Institution, 59a Beskudnikovskiy blvd, Moscow, Russian Federation, 127486

List of references:

Dedova II, Shestakova MV, Mayorova AYu. i dr. Standards of specialized diabetic care. Sakharnyi diabet. Klinicheskie rekomendacii. 8-j vipysk. 2017;20(1S):1-121. (In Russ.).
Neroev VV, Zaytseva OV, Mikhailova LA. Incidence of diabetic retinopathy in the Russian Federation according to Federal statistics. Rossiyskij oftal’mologicheskij jurnal. 2018;11(2):5-9. (In Russ.). https://doi.org/10.21516/2072-0076-2018-11-2-5-9
Wells JA, Glassman AR, Ayala AR et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. N Engl J Med. 2015;372:1193-1203. https://doi.org/10.1056/NEJMoa1414264
Bressler SB, Ayala AR, Bressler NM,et al. Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment. JAMA Ophthalmol. 2016;134(3):278-285. https://doi.org/10.1001/jamaophthalmol.2015.5346
Tao L, Wu Z, Guymer R, Luu C. Ellipsoid zone on optical coherence tomography: a review. Clin Experiment Ophthalmol. 2016;44(5):422-430. https://doi.org/10.1111/ceo.12685
Muftuoglu I, Mendoza N, Gaber R et al. Integrity of outer retinal layers after resolution of central involved diabetic macular edema. Retina. 2017;37(11):2015-2024. https://doi.org/10.1097/iae.0000000000001459
Sun J, Lin M, Lammer J, et al. Disorganization of the Retinal Inner Layers as a Predictor of Visual Acuity in Eyes With Center-Involved Diabetic Macular Edema. JAMA Ophthalmol. 2014;132(11):1309. https://doi.org/10.1001/jamaophthalmol.2014.2350
Vujosevic S, Torresin T, Bini S, et al. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema. Acta Ophthalmol. 2016;95(5):464-471. https://doi.org/10.1111/aos.13294
Vujosevic S, Torresin T, Berton M, et al. Diabetic Macular Edema With and Without Subfoveal Neuroretinal Detachment: Two Different Morphologic and Functional Entities. Am J Ophthalmol. 2017;181:149-155. https://doi.org/10.1016/j.ajo.2017.06.026
Fursova AZh, Chubar’ NV, Tarasov MS. et al. Clinical parallels of the relationship between the state of retinal photoreceptors and reparation of visual functions in diabetic macular edema. Vestnik oftal’mologii. 2017;133(1):11-18. (In Russ.). https://doi.org/10.17116/oftalma2017133111-18
Shin H, Lee S, Chung H, Kim H. Association between photoreceptor integrity and visual outcome in diabetic macular edema. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2011;250(1):61-70. https://doi.org/10.1007/s00417-011-1774-x
Matsumoto H, Sato T, Kishi S. Outer Nuclear Layer Thickness at the Fovea Determines Visual Outcomes in Resolved Central Serous Chorioretinopathy. Am J Ophthalmol. 2009;148(1):105-110.e1. https://doi.org/10.1016/j.ajo.2009.01.018
Pelosini L, Hull C, Boyce J, et al. Optical Coherence Tomography May Be Used to Predict Visual Acuity in Patients with Macular Edema. Investigative Ophthalmology & Visual Science. 2011;52(5):2741-2748. https://doi.org/10.1167/iovs.09-4493
Santos A, Costa M, Schwartz C, et al. Optical coherence tomography baseline predictors for initial best-corrected visual acuity response to intravitreal anti-vascular endothelial growth factor treatment in eyes with diabetic macular edema. Retina. 2018;38(6):1110-1119. https://doi.org/10.1097/iae.0000000000001687
Das R, Spence G, Hogg RE, et al. Disorganization of Inner Retina and Outer Retinal Morphology in Diabetic Macular Edema. JAMA Ophthalmol. 2018;136(2):202-208. https://doi.org/10.1001/jamaophthalmol.2017.6256
Framme C, Schweizer P, Imesch M et al. Behavior of SD-OCT — Detected Hyperreflective Foci in the Retina of Anti-VEGF — Treated Patients with Diabetic Macular Edema. Investigative Opthalmology & Visual Science. 2012;53(9):5814. https://doi.org/
Phadikar P, Saxena S, Ruia S et al. The potential of spectral domain optical coherence tomography imaging based retinal biomarkers. Int J Retina Vitreous. 2017;3(1):2-10. https://doi.org/10.1186/s40942-016-0054-7
Vujosevic S, Toma C, Villani E, et al. Diabetic macular edema with neuroretinal detachment: OCT and OCT-angiography biomarkers of treatment response to anti-VEGF and steroids. Acta Diabetol. 2019;1-10. https://doi.org/10.1007/s00592-019-01424-4
Campos A, Campos E, Martins J, et al. Viewing the choroid: where we stand, challenges and contradictions in diabetic retinopathy and diabetic macular oedema. Acta Ophthalmol. 2016;95(5):446-459. https://doi.org/10.1111/aos.13210
Bressler S. Factors Associated With Changes in Visual Acuity and Central Subfield Thickness at 1 Year After Treatment for Diabetic Macular Edema With Ranibizumab. Archives of Ophthalmology. 2012;130(9):1153. https://doi.org/10.1001/archophthalmol.2012.1107
Wong WL. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):106-116. https://doi.org/10.1016/S2214-109X(13)70145-1
Pedanova EK, Doga AV. Treatment of polypoid choroidal vasculopathy: photodynamic therapy, anti-VEGF therapy, or their combination? Review study. Oftal’mologiya. 2019;16(2):151-158. (In Russ.). https://doi.org/10.18008/1816-5095-2019-2-151-158
Honda S, Matsumiya W, Negi A. Polypoidal choroidal vasculopathy: clinical features and genetic predisposition. Ophthalmologica. 2014;231(2):59-74. https://doi.org/10.1159/000355488
Hatz K, Prunte C. Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response. Br J Ophthalmol. 2014;98(2):188-194. https://doi.org/10.1136/bjophthalmol-2013-303444
Kokame GT, deCarlo TE, Kaneko KN, et al. Anti-Vascular Endothelial Growth Factor Resistance in Exudative Macular Degeneration and Polypoidal Choroidal Vasculopathy. Ophthalmol Retina. 2019;3(9):744-752. https://doi.org/10.1016/j.oret.2019.04.018
Gomi F, Sawa M, Sakaguchi H, et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2008;92(1):70-73. https://doi.org/10.1136/bjo.2007.122283
Kang HM, Koh HJ. Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2013;156(4):652-660. https://doi.org/10.1016/j.ajo.2013.05.038
Koh A, Lai TYY, Takahashi K, et al. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol. 2017;135(11):1206-1213. https://doi.org/10.1001/jamaophthalmol.2017.4030
Mayorova AM, Doga AV, Pedanova EK. Clinical and functional results of combination therapy of polypoid choroidal vasculopathy. Prakticheskaya medicina. 2018;114(3):114-117. (In Russ.).
Wong TY, Ogura Y, Lee WK, Iida T, et al. Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy: 2-Year Results of the PLANET Study. Am J Ophthalmol. 2019;204:80-89. https://doi.org/10.1016/j.ajo.2019.02.027
Wolff B, Vasseur V, Cahuzac A, et al. Aflibercept Treatment in Polypoidal Choroidal Vasculopathy: Results of a Prospective Study in a Caucasian Population. Ophthalmologica. 2018;240(4):208-212. https://doi.org/10.1159/000488808
Hata M, Oishi A, Yamashiro K. et al. Incidence and causes of vision loss during aflibercept treatment for neovascular age-related macular degeneration: One-Year Follow-up. Retina. 2017;37(7):1320-1328. https://doi.org/10.1097/IAE.0000000000001370
Schmidt-Erfurth U, Waldstein SM, Deak GG, et al. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology. 2015;122(4):822-832. https://doi.org/10.1016/j.ophtha.2014.11.017
Pepple K, Mruthyunjaya P. Retinal pigment epithelial detachments in age-related macular degeneration: classification and therapeutic options. Semin Ophthalmol. 2011;26(3):198-208. https://doi.org/10.3109/08820538.2011.570850
Cho HJ, Kim KM, Kim HS, et al. Response of Pigment Epithelial Detachment to Anti-Vascular Endothelial Growth Factor Treatment in Age-Related Macular Degeneration. Am J Ophthalmol. 2016;166:112-119. https://doi.org/10.1016/j.ajo.2016.03.039
Chen X, Al-Sheikh M, Chan CK, et al. Type 1 versus type 3 neovascularization in pigment epithelial detachments associated with age-related macular degeneration after anti-vascular endothelial growth factor therapy: A Prospective Study. Retina. 2016;36(suppl 1):50-64. https://doi.org/10.1097/IAE.0000000000001271
Saddha SR, Guymer R, Holz FG, et al. Consensus Definition for Atrophy Associated With Age-Related Macular Degeneration on OCT: Classification of Atrophy Report 3. Ophthalmology. 2018;125:537-548. https://doi.org/10.1016/j.ophtha.2017.09.028
Kashani AH. Stem Cell Therapy in Non-Neovascular Age-Related Macular Degeneration Stem Cell Therapy in Non-Neovascular AMD. Investigative Ophthalmology & Visual Science. 2016;57(5):1-9. https://doi.org/10.1167/iovs.15-17681
Gune S, et al. Spectral-Domain OCT—Based Prevalence and Progression of Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2019;1-10. https://doi.org/10.1016/j.ophtha.2019.09.030
Bhisitkul RB, Desai SJ, Boyer DS, et al. Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects From ANCHOR, MARINA, and HORIZON (SEVEN-UP Study). Ophthalmology. 2016;123:1269-1277. https://doi.org/10.1016/j.ophtha.2016.01.033
Michels S. The ‘Switch’ and Macular Atrophy in nAMD. Retina Specialist. 2017.
Gillies M, et al. A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients (RIVAL). Abstract at EURETINA 2019, Free Paper Session 15: AMD III Session 2.

Close metadata